
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.
Jason R. Gotlib discusses JAK inhibitors for the treatment of patients with myelofibrosis.
Jason R. Gotlib, associate professor of Medicine (Hematology) at Stanford University Medical Center, discusses JAK inhibitors for the treatment of patients with myelofibrosis.
Gotlib discusses whether next-generation JAK inhibitors should be used after resistance to Jakafi (ruxolitinib) or in the frontline setting. Gotlib also provided an overview of drugs that are being studied in combination with these agents.
Gotlib is a






